Tumor cell surface stress-induced NKG2D ligands (NKG2DL)

Tumor cell surface stress-induced ligands for NKG2D, commonly known as NKG2DL, are a diverse family of cell surface proteins upregulated on stressed, infected, or transformed cells, including tumors, to signal danger to the immune system. These ligands bind to the activating receptor NKG2D on natural killer (NK) cells and certain T cells, triggering cytotoxicity through perforin/granzyme release and cytokine production like IFN-γ, thereby promoting tumor immunosurveillance and rejection.[1][2][3] In cancer, NKG2DL expression (e.g., MICA, MICB, ULBPs in humans; MULT1, RAE-1 in mice) is induced by DNA damage responses or oncogenic stress, enabling NK cells to target malignant cells, though tumors often evade this by shedding soluble forms (sNKG2DL) that downregulate NKG2D and impair effector function.[1][3][4][6] This dual role—membrane-bound forms activate immunity while soluble forms suppress it—makes NKG2DL a key player in tumor immune escape, with high sMICA/MICB levels linked to advanced disease and poor outcomes in cancers like breast, melanoma, and leukemia.[3][6] Therapeutically, strategies include drugs like HDAC inhibitors (romidepsin, entinostat) or cytokines (IL-2, IL-15) to boost NKG2DL or NKG2D expression, and blocking soluble ligands to restore NK activity, positioning the pathway as a promising target for immunotherapy despite challenges like NK cell desensitization from chronic exposure.[1][3][4]

Other names

NKG2D ligandsstress-induced ligandsMICAMICBULBP1-6MULT1RAE-1

Upregulate NKG2DL expression on tumor cells to enhance NK cell cytotoxicity, Block soluble NKG2DL to prevent NKG2D downregulation, Increase NKG2D receptor expression on immune cells